Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merlin L Robb

Showing results (11-20 of 358) with videos related to

Pageof 36
Sort By:
The New England Journal of Medicine|September 23, 2016
Acute HIV-1 Infection in Adults in East Africa and ThailandMerlin L Robb, Leigh A Eller, Morgane Rolland
Human Vaccines & Immunotherapeutics|March 19, 2014
HIV-1 vaccines: challenges and new perspectivesJean-Louis Excler, Merlin L Robb, Jerome H Kim
American Journal of Preventive Medicine|November 23, 2015
Prospects for a Globally Effective HIV-1 VaccineJean-Louis Excler, Merlin L Robb, Jerome H Kim
Vaccine|June 24, 2015
Prospects for a globally effective HIV-1 vaccineJean-Louis Excler, Merlin L Robb, Jerome H Kim
Journal of Translational Medicine|December 14, 2011
Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applicationsJeffrey R Currier, Merlin L Robb, Nelson L Michael, et al.
Expert Review of Vaccines|September 9, 2010
Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1Robert M Paris, Jerome H Kim, Merlin L Robb, et al.
Plos Computational Biology|June 7, 2019
The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopesHongjun Bai, Yifan Li, Nelson L Michael, et al.
Plos One|June 10, 2010
W-curve alignments for HIV-1 genomic comparisonsDouglas J Cork, Steven Lembark, Sodsai Tovanabutra, et al.
Clinical and Vaccine Immunology : CVI|June 13, 2014
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesJean-Louis Excler, Julie Ake, Merlin L Robb, et al.
Vaccine: X|May 2, 2023
Preparing for future European efficacy trials of interventions to prevent HIV and other sexually transmitted infections: Lessons on willingness to participate and barriers to participation from ten German clinics serving behaviorally vulnerable men who have sex with menAllahna L Esber, Klaus Jansen, Julie Dorsey-Spitz, et al.
Pageof 36

Showing results (11-20 of 358) with videos related to

Sort By:
Pageof 36
The New England Journal of Medicine|September 23, 2016
Acute HIV-1 Infection in Adults in East Africa and ThailandMerlin L Robb, Leigh A Eller, Morgane Rolland
Human Vaccines & Immunotherapeutics|March 19, 2014
HIV-1 vaccines: challenges and new perspectivesJean-Louis Excler, Merlin L Robb, Jerome H Kim
American Journal of Preventive Medicine|November 23, 2015
Prospects for a Globally Effective HIV-1 VaccineJean-Louis Excler, Merlin L Robb, Jerome H Kim
Vaccine|June 24, 2015
Prospects for a globally effective HIV-1 vaccineJean-Louis Excler, Merlin L Robb, Jerome H Kim
Journal of Translational Medicine|December 14, 2011
Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applicationsJeffrey R Currier, Merlin L Robb, Nelson L Michael, et al.
Expert Review of Vaccines|September 9, 2010
Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1Robert M Paris, Jerome H Kim, Merlin L Robb, et al.
Plos Computational Biology|June 7, 2019
The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopesHongjun Bai, Yifan Li, Nelson L Michael, et al.
Plos One|June 10, 2010
W-curve alignments for HIV-1 genomic comparisonsDouglas J Cork, Steven Lembark, Sodsai Tovanabutra, et al.
Clinical and Vaccine Immunology : CVI|June 13, 2014
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesJean-Louis Excler, Julie Ake, Merlin L Robb, et al.
Vaccine: X|May 2, 2023
Preparing for future European efficacy trials of interventions to prevent HIV and other sexually transmitted infections: Lessons on willingness to participate and barriers to participation from ten German clinics serving behaviorally vulnerable men who have sex with menAllahna L Esber, Klaus Jansen, Julie Dorsey-Spitz, et al.
Pageof 36